Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

CXXC1 is required for IRF4 chromatin binding and expression and regulates cellular fitness in lenalidomide-sensitive and -resistant myeloma cells

Pierangela Sabbattini, Nikolaos Trasanidis, Jason Taslim et al. Nov 03, 2025 pp. 571-571 10.1182/blood-2025-571

Abstract IRF4 is a plasma cell lineage-defining transcription factor that orchestrates important aspects of the oncogenic transcriptome in m...

NF-κB is a potential therapeutic target for histone deacetylase inhibitor-resistant cutaneous T-cell lymphoma

Akihiro Kitadate, Yuto Takahashi, Sayaka Iwama et al. Nov 03, 2025 pp. 6825-6825 10.1182/blood-2025-6825

Abstract Background: Cutaneous T-cell lymphoma (CTCL) is a malignant T-cell lymphoma that proliferates and progresses in the skin. Advanced-...

Trial in progress: A phase 3, multi-regional, open-label, randomized study of tirabrutinib vs rituximab and temozolomide in participants with Relapsed/Refractory primary central nervous system lymphoma

Christian Grommes, Lakshmi Nayak, Charles Psoinos et al. Nov 03, 2025 pp. 3703-3703 10.1182/blood-2025-3703

Abstract Background and Significance Primary central nervous system lymphoma (PCNSL) is a rare, highly aggressive form of non-Hodgkin lymphom...

Time-dependent long short-term memory neural cox regression in 2,690 patients with myeloid neoplasias treated with diverse therapies identifies bone marrow related information to be less important than expected in the context of other available clinical parameters: Insights from the AML-001 trial (NCT01074047) and the austrian myeloid registry (NCT04438889) of the AGMT study group

Lisa Pleyer, Xu Zhang, Manuel Drost et al. Nov 03, 2025 pp. 48-48 10.1182/blood-2025-48

Abstract Introduction Morphologic complete remission (CR) or composite CR (cCR), requiring bone marrow evaluations (BMEs), remains the stand...

Evaluating ribosomal readthrough as a precision medicine strategy for restoring factor VIII expression in hemophilia a

Zhigang Liu, Vishal Srivastava, Aabid Hussain et al. Nov 03, 2025 pp. 4829-4829 10.1182/blood-2025-4829

Abstract Current prophylactic treatments for hemophilia A (HA) primarily rely on factor replacement therapies, which consist of intravenous...

CD3⁺cell dose is an independent risk factor for grade II–IV aGVHD following cord blood transplantation in children with aplastic anemia

Jian-Ping Zhang, Li Nannan, Min Xiong et al. Nov 03, 2025 pp. 7752-7752 10.1182/blood-2025-7752

Abstract Introduction Cord blood transplantation (CBT) has been widely used in hematologic malignancies with favorable outcomes. The use of...

Preliminary safety and efficacy of anti-CD19/CD20 bispecific CAR-T cell therapy (JWCAR201) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: Results from an ongoing phase I study

Wenhao Zhang, Rong Tao, Chuanxu Liu et al. Nov 03, 2025 pp. 6088-6088 10.1182/blood-2025-6088

Abstract Background Relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) represents a significant therapeutic challenge, with...

A blood-based protein signature adds to genomic prognostication of survival in TP53-mutated Acute Myeloid Leukemia

Sara Nofal, Jennifer Marvin-Peek, Sanam Loghavi et al. Nov 03, 2025 pp. 3503-3503 10.1182/blood-2025-3503

Abstract Background Outcomes for patients (pts) with newly diagnosed acute myeloid leukemia (AML) have improved significantly with the advent...

Decoding multi-compartmental immune pathways in antibody-mediated and dose-stratified murine TRALI via high-dimensional cytometry and targeted proteomics

Farahnaz Rayatdoost, Simon Tol, Kim Luesken et al. Nov 03, 2025 pp. 541-541 10.1182/blood-2025-541

Abstract Transfusion-related acute lung injury (TRALI) remains one of the most severe and under-treated complications of blood transfusion....

Clinical significance of blood EBV-DNA in peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) and EBV-positive nodal T-cell lymphoma

Hyunseok Yoon, Sejin Kim, So Heun Lee et al. Nov 03, 2025 pp. 3654-3654 10.1182/blood-2025-3654

Abstract Background: Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS), is a predominantly nodal, diagnosis-of-exclusion entity...

Outcomes and prognostic factors in patients with follicular lymphoma treated with front-line bendamustine and rituximab

Hari Raman, Robert Redd, Wendy Dixon et al. Nov 03, 2025 pp. 1812-1812 10.1182/blood-2025-1812

Abstract Background Combination therapy with bendamustine and rituximab (BR) is a safe and effective front-line regimen in patients with fol...

The CDK7 inhibitor THZ1 overcomes venetoclax resistance in acute myeloid leukemia through dual regulation of p53 signaling and transcriptional networks

Weidong Ding, Xiaoya Yun, Yifan Liu et al. Nov 03, 2025 pp. 6796-6796 10.1182/blood-2025-6796

Abstract Background: Venetoclax (Ven), a selective BCL-2 inhibitor, has shown clinical efficacy in AML, but the mechanisms underlying resist...

The influence of racial, socioeconomic, and geographic disparities in the survival of patients with plasmablastic lymphoma: A population-based analysis from the surveillance, epidemiology, and end Results (SEER) database (2000–2022).

Imran Khan, Mohammad Ebad Ur Rehman, Abat Khan et al. Nov 03, 2025 pp. 1903-1903 10.1182/blood-2025-1903

Abstract Background: Plasmablastic lymphoma (PBL) is a rare, aggressive subtype of large B-cell lymphoma with poor outcomes and limited popu...

Immune deconvolution from whole transcriptomic data suggests expansion of exhausted T-cells and natural killer cells following tyrosine kinase inhibitor therapy in chronic myeloid leukemia patients

Yael Morgenstern, Amirthagowri Ambalavanan, Jae-Sook Ahn et al. Nov 03, 2025 pp. 1991-1991 10.1182/blood-2025-1991

Abstract Introduction Tyrosine kinase inhibitor (TKI) therapy, while targeting leukemic cells, also alters the immune landscape in chronic m...

Granulocyte maturation and splicing defects in DDX41-mutated leukemia

Ira Kraft, Jeremy Scutenaire, Ayush Raman et al. Nov 03, 2025 pp. 1439-1439 10.1182/blood-2025-1439

Abstract Deleterious germ line DEAD-box helicase 41 (DDX41) variants cause an inherited predisposition to adult-onset acute myeloid leukemia...

Preliminary safety and efficacy of the frida study: Iadademstat and gilteritinib in FLT3-mutated relapsed/refractory acute myeloid leukemia

Sangeetha Venugopal, Neil Palmisiano, Guru Subramanian Guru Murthy et al. Nov 03, 2025 pp. 5197-5197 10.1182/blood-2025-5197

Abstract Background: Fms-related tyrosine kinase 3 (FLT3) mutations occur in 30-40% of patients (pts) with AML (frontline and relapsed/refra...

CRLF2-rearrangement and extramedullary disease in B-cell acute lymphoblastic leukemia: A possible link?

Flavia Mesquita Gava, Bonnie Yates, Grace Li et al. Nov 03, 2025 pp. 5099-5099 10.1182/blood-2025-5099

Abstract Introduction: Cytokine receptor-like factor 2 rearrangement (CRFL2r), a Philadelphia chromosome-like (Ph-like) aberration, is a poo...

More than IL-2: Optimizing feeder-free NK cell function through cytokine synergy

Maxima Warmuzová, Klára Baďurová, Zuzana Chyra et al. Nov 03, 2025 pp. 5966-5966 10.1182/blood-2025-5966

Abstract Introduction Natural killer (NK) cells represent a promising therapeutic immune cell sources for the treatment...

Transitioning from FISH to NGS for immunoglobulin translocation detection in multiple myeloma

Christophe Legendre, Bryce Turner, Shari Kyman et al. Nov 03, 2025 pp. 5724-5724 10.1182/blood-2025-5724

Abstract The International Myeloma Society and International Myeloma Working Group recently updated the definition of high-risk multiple mye...

Real-world comparative bleeding outcomes of direct oral anticoagulants versus warfarin in adults: Insights from observational evidence

Manpal Sandhu, Asrith Reddy Gandu, Sukhmanpreet Kaur Sandhu et al. Nov 03, 2025 pp. 6678-6678 10.1182/blood-2025-6678

Abstract Background: Direct oral anticoagulants (DOACs) – apixaban, rivaroxaban, dabigatran, and edoxaban– are increasingly preferred over w...

Real-time interleukin-6 (IL-6) kinetics predict cytokine release syndrome (CRS) in patients receiving chimeric antigen receptor (CAR) T-cell therapy for Relapsed/Refractory B-cell malignancies

Agrima Mian, Rafaella Ferreira De Araujo Litvin, Jessica Colon-Franco et al. Nov 03, 2025 pp. 2397-2397 10.1182/blood-2025-2397

Abstract Background Cytokine release syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity Syndrome (ICANS) are common, potential...

Mismatched unrelated and haploidentical transplant with post-transplant cyclophosphamide-based graft versus host disease prophylaxis are effective for myelofibrosis

Richard Sheppard, Noa Rippel, Hulya Kocyigit et al. Nov 03, 2025 pp. 2530-2530 10.1182/blood-2025-2530

Abstract Background Allogeneic hematopoietic cell transplant (HCT) remains the only curative option for myelofibrosis (M...

Do chip mutations predict frailty and toxicity in transplant-eligible patients with multiple myeloma?

Steven Chun-Min Shih, Harjot Singh Vohra, Sahar Khan et al. Nov 03, 2025 pp. 5773-5773 10.1182/blood-2025-5773

Abstract Background We have previously reported that current frailty tools have limited ability to predict treatment-related toxicity in tra...

Treatment patterns and outcomes for large B-cell lymphoma patients with central nervous system relapse: A multicenter retrospective study (CoNSensus Study)

Hirokazu Sasaki, Tomotaka Suzuki, Dai Maruyama et al. Nov 03, 2025 pp. 5435-5435 10.1182/blood-2025-5435

Abstract Background: Secondary central nervous system lymphoma (SCNSL) occurs in patients (pts) with large B-cell lymphoma (LBCL) and is ass...

Total body irradiation and cigarette smoking interact to increase the risk of lung cancer in blood or marrow transplant (BMT) survivors – a BMTSS report

Nora Balas, Yanjun Chen, Qingrui Meng et al. Nov 03, 2025 pp. 1055-1055 10.1182/blood-2025-1055

Abstract Introduction: Chest radiation-related lung cancer has been previously reported in cancer survivors (Lorigan et al, Lancet Oncology,...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page